Skip to content
OpenCapital
Get started

Bristol-Myers Squibb BMY United States — Total Revenues

Other financials

Income statement

See full
Revenue$11.5B+2.6%
Gross profit$8.1B-1.2%
Net income$2.7B+9.0%
EPS (diluted)$1.31+9.2%

Balance sheet

See full
Cash & equivalents$9.6B-12.0%
Total debt$44.7B-10.5%
Total equity$20.1B+15.4%
Total assets$86.5B-6.4%

Cash flow

See full
Operating cash flow$1.1B-43.5%
CapEx$347.0M+33.5%
Free cash flow$757.0M-55.3%

Valuation

See full
Market cap$118.32B+25.1%
Enterprise value$153.4B+16.8%
P/E16.3×-2.7×
P/S2.4×+0.5×

Profitability

See full
Gross margin70.5%0.0pp
Net margin15%+3.8pp
FCF margin24.6%-2.9pp

Returns & leverage

See full
Return on equity38.8%+7.3pp
Debt / equity2.2×-0.6×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Bristol-Myers Squibb in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bristol-Myers Squibb's united states — total revenues.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bristol-Myers Squibb's united states — total revenues?
Bristol-Myers Squibb (BMY) reported united states — total revenues of $7.79B in Q1 2026.
How has Bristol-Myers Squibb's united states — total revenues changed year-over-year?
Bristol-Myers Squibb's united states — total revenues decreased by 1.1% year-over-year, from $7.87B to $7.79B.
What is the long-term trend for Bristol-Myers Squibb's united states — total revenues?
Over 4 years (2021 to 2025), Bristol-Myers Squibb's united states — total revenues has grown at a 3.3% compound annual growth rate (CAGR), from $29.21B to $33.28B.